New generation of microplate readers
Biochrom has a new generation of microplate readers, tailored to meet the needs of modern labs
Lab workers can now benefit from the cost-effective and easy to use instrument. Offering flexibility and full performance with no redundant features, the filter-based, PC-controlled EZ Read 400 can be tailored to suit application requirements.
The ability to perform single or dual wavelength measurements to incorporate reference wavelength readings, and the option to do so at timed-intervals, means the EZ Read 400 is ideal for ELISA, protein, cell biology and kinetic assays.
Designed to take up the minimum of bench space, and incorporating ADAP Basic PC software and USB connections for easy instrument connection and data transfer, the new EZ Read 400 can be configured with a choice of filter options within a wavelength range of 400-750 nm , a choice of data analysis software packages and a QC plate for instrument validation.
You may also like
Trending Articles
You may also like
Manufacturing
BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech
The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Manufacturing
Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform
The pair will work to enhance CAR NK cell therapy manufacturing efficiency, combining Miltenyi Bioindustry's baboon envelope lentiviral vector platform with CHA Biotech's NK cell research expertise to improve gene delivery, scalability and cost of goods
Manufacturing
Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market
Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA
Manufacturing
FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing
A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain